Regulus Therapeutics

Nov 09, 2023

•

Sep 30, 2023

Regulus Therapeutics Q3 2023 Earnings Report

Reported financial results for the third quarter ended September 30, 2023.

Key Takeaways

Regulus Therapeutics reported positive topline data from the first cohort of patients in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The company's cash, cash equivalents and short-term investments were $30.8 million as of September 30, 2023.

Announced positive topline data from the first cohort of patients in Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD).

Completed enrollment in the second cohort of the Phase 1b MAD Clinical Trial of RGLS8429 for the Treatment of ADPKD.

First patient dosed in the third cohort of the Phase 1b MAD Clinical Trial of RGLS8429 for the Treatment of ADPKD.

Cash, cash equivalents and short-term investments totaled $30.8 million as of September 30, 2023.

Research and development expenses

$5.5M

General and administrative expenses